(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/207820 A2

(51) International Patent Classification:
C07K 14/46 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2025/021631

(22) International Filing Date:
26 March 2025 (26.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/570,724 27 March 2024 (27.03.2024) US

(71) Applicant: **MEDIAR THERAPEUTICS, INC.** [US/US]; 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US).

(72) Inventors: **TAVARES, Daniel**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US). **HIGGINSON-SCOTT, Nathan**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US). **YAWORSKY, Paul**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US). **KIPRONO, Timothy**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US). **DEVINE, Erin**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US). **ESPELIN, Christopher**; c/o MEDIAR THERAPEUTICS, INC., 20 Overland Street, Suite 520, Boston, Massachusetts 02215 (US).

(74) Agent: **CHEN, Yuwei**; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 3580 Carmel Mountain Road, Suite 300, San Diego, California 92130 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ANTI-EPHRIN B2 ANTIBODIES AND METHODS OF USE

(57) Abstract: Provided herein are antibodies and antibody fragments, which specifically bind Ephrin B2 protein. The anti-Ephrin B2 antibodies provided herein bind Ephrin B2 protein with high affinity and specificity. The anti-Ephrin B2 antibodies are contemplated to be effective for treating and preventing fibrosis in a subject in need thereof.

FIG. 14A



WO 2025/207820 A2

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*